| Autor: |
Rentsch V; Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland., Seipel K; Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland., Banz Y; Institute of Pathology, Inselspital, University of Bern, 3008 Bern, Switzerland., Wiedemann G; Center of Laboratory Medicine (ZLM), Inselspital, Bern University Hospital, 3010 Bern, Switzerland., Porret N; Center of Laboratory Medicine (ZLM), Inselspital, Bern University Hospital, 3010 Bern, Switzerland., Bacher U; Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland., Pabst T; Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland. |
| Abstrakt: |
Chimeric antigen receptor T-cells (CAR T) treatment has become a standard option for patients with diffuse large B-cell lymphomas (DLBCL), which are refractory or relapse after two prior lines of therapy. However, little evidence exists for treatment recommendations in patients who relapse after CAR T-cell treatment and the outcome for such patients is poor. In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. The patients received a maximum of 12 cycles of glofitamab after a single obinutuzumab pre-treatment at an academic institution. CRS was observed in two patients (grade 2 in both patients). We observed an overall response rate of 67%, with four patients achieving a complete response and a partial remission in two patients. Interestingly, we identified increased persistence of circulating CAR T-cells in peripheral blood in three of the five patients with measurable CAR T-cells. Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity. |
